Cytokinetics, Incorporated (CYTK)

NASDAQ: CYTK · IEX Real-Time Price · USD

54.84

+0.14 (0.26%)

At close: Jul 2, 2024, 4:00 PM

53.89

-0.96 (-1.74%)

After-hours: Jul 2, 2024, 4:41 PM EDT

Cytokinetics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2001
Net Income	-526.24	-388.96	-215.31	-127.29	-121.69	Upgrade
Depreciation & Amortization	11.89	5.81	2.28	1.83	1.29	Upgrade
Share-Based Compensation	72.07	47.85	26.83	17.62	10.76	Upgrade
Other Operating Activities	27.95	35.77	43.68	116.78	18.73	Upgrade
Operating Cash Flow	-414.33	-299.52	-142.52	8.94	-90.91	Upgrade
Capital Expenditures	-1.42	-11.34	-48.87	-11.05	-2.62	Upgrade
Change in Investments	240.67	-250.8	-98.91	-185.46	-72.09	Upgrade
Investing Cash Flow	239.25	-262.13	-147.78	-196.52	-74.71	Upgrade
Share Issuance / Repurchase	182.69	17.54	324.43	234.23	37.61	Upgrade
Debt Issued / Paid	-0.86	332.25	0	0	122.18	Upgrade
Other Financing Activities	39.48	166.37	-4.45	-0.1	-	Upgrade
Financing Cash Flow	221.32	516.17	319.98	234.12	159.79	Upgrade
Exchange Rate Effect	-0.02	0	0	0	0	Upgrade
Net Cash Flow	46.22	-45.48	29.68	46.55	-5.82	Upgrade
Free Cash Flow	-415.75	-310.85	-191.39	-2.11	-93.53	Upgrade
Free Cash Flow Margin	-5521.24%	-328.64%	-271.76%	-3.78%	-348.09%	Upgrade
Free Cash Flow Per Share	-4.31	-3.46	-2.49	-0.03	-1.62	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).